Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CPI-444 (V81444) 是一种选择性的,可口服的 A2A 受体 (A2AR) 拮抗剂,可诱导抗肿瘤反应。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 393 | 现货 | ||
5 mg | ¥ 956 | 现货 | ||
10 mg | ¥ 1,580 | 现货 | ||
25 mg | ¥ 2,950 | 现货 | ||
50 mg | ¥ 4,390 | 现货 | ||
100 mg | ¥ 6,280 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,090 | 现货 |
产品描述 | CPI-444 (V81444) is an antagonist of the adenosine A2A receptor.It reduces tumor area in mouse model of murine Her2/neu-expressing breast cancer. |
体内活性 | CPI-444 is a potent, oral, selective A2AR antagonist that has been well tolerated in Ph 1/1b studies in non-oncology indications.?CPI-444 is being investigated in a Ph 1b study in solid tumors as a single agent and in combination with the anti-PD-L1 antibody atezolizumab.?In preclinical studies, daily treatment of the syngeneic mouse model MC38 with CPI-444 (1, 10, 100 mg/kg) led to dose-dependent inhibition of tumor growth, leading to tumor elimination in ~30% of treated mice.?Combining CPI-444 (100 mg/kg, qd, 14 days) with anti-PD-L1 (200 μg, 3qw, 4 doses) treatment in MC38 models synergistically inhibited tumor growth and eliminated tumors in 90% of treated mice.?When cured mice were later re-challenged with MC38 cells, tumor growth was rejected in 100% of challenged mice, indicating that CPI-444 induced systemic anti-tumor immune memory.?CD8+ T cell depletion abrogated the efficacy of CPI-444 treatment as a single agent as well as in combination with anti-PD-L1, demonstrating a role for CD8+ T cells in mediating primary and secondary immune responses.?Anti-tumor efficacy of CPI-444 ± anti-PD-L1 was associated with increased CD8+ cell infiltration and activation in MC38 tumor tissues, and a corresponding rise in PD-1 expression on CD8+ T cells in the spleen[1]. |
别名 | V81444, ciforadenant |
分子量 | 407.43 |
分子式 | C20H21N7O3 |
CAS No. | 1202402-40-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 67.5 mg/mL (165.67 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.4544 mL | 12.272 mL | 24.5441 mL | 61.3602 mL |
5 mM | 0.4909 mL | 2.4544 mL | 4.9088 mL | 12.272 mL | |
10 mM | 0.2454 mL | 1.2272 mL | 2.4544 mL | 6.136 mL | |
20 mM | 0.1227 mL | 0.6136 mL | 1.2272 mL | 3.068 mL | |
50 mM | 0.0491 mL | 0.2454 mL | 0.4909 mL | 1.2272 mL | |
100 mM | 0.0245 mL | 0.1227 mL | 0.2454 mL | 0.6136 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
CPI-444 1202402-40-1 GPCR/G Protein Neuroscience Adenosine Receptor P1 receptor CPI444 Inhibitor V81444 CPI 444 V-81444 ciforadenant V 81444 inhibit inhibitor